Related Experiment Video
Updated: May 27, 2026
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Ziconitide
1Department of Pain Medicine and Anesthesiology, University of California Davis Medical Center, Sacramento, California 95817, USA. engreenberg@ucdavis.edu
Journal of Pain & Palliative Care Pharmacotherapy
|December 1, 2011
Summary
Ziconotide, a pain management drug derived from snail venom, offers a novel therapeutic option for severe and chronic pain. This query addresses its uses and potential side effects for patient education.
Area of Science:
- Pharmacology
- Pain Management
- Drug Discovery
Background:
- Severe and chronic pain conditions pose significant challenges to patient quality of life.
- Existing analgesic pharmacotherapies may have limitations in efficacy or side effect profiles.
- Novel therapeutic targets and agents are continuously being investigated for pain management.
Purpose of the Study:
- To educate patients on ziconotide, a new drug for severe and chronic pain.
- To provide information on the uses of ziconotide.
- To outline the potential side effects associated with ziconotide therapy.
Main Methods:
- This content is based on patient-authored questions and expert author responses.
- Information is synthesized from existing literature and clinical knowledge regarding ziconotide.
- The focus is on patient-centric education regarding a specific analgesic.
Main Results:
- Ziconotide is a synthetic peptide modeled from a component of snail venom.
- It acts as a selective blocker of N-type voltage-gated calcium channels in the central nervous system.
- This mechanism of action provides analgesia without the typical side effects of opioids.
Conclusions:
- Ziconotide represents a novel pharmacological approach for managing severe and chronic pain.
- Understanding its uses and potential side effects empowers patients to be more informed self-advocates.
- Further research and clinical experience will continue to refine the role of ziconotide in pain management.
More Related Videos
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...